

## Oryzon to attend the 32nd ANNUAL J.P. MORGAN Healthcare Conference in San Francisco

The company will also present its advances in its LSD1 programs at the Biotech-Showcase 2014 parallel meeting

Barcelona, December 16th, 2013. Oryzon announced today that its C.E.O. Dr. Buesa will attend the 32nd ANNUAL J.P. MORGAN Healthcare Conference on JANUARY 13–16, 2014 at the Westin St. Francis to discuss with the leaders of the industry the potential of epigenetics in devastating diseases.

The company will also participate at the parallel event Biotech Showcase 2014 where it will present the advances in its Alzheimer's disease program on Jan 15th 2014 at 9:45:00 on the Track B - Mission I (4th Floor) to be held at the Parc55 Wyndham-Union Square Hotel.

Barcelona, Spain. December 16th, 2013.

The J.P. Morgan HealthCare Conference brings together industry leaders, financial sponsors and investors to explore innovation, market and trends in the pharmaceutical industry. Epigenetics is certainly one of the most innovative areas and ORYZON will have, for the second consecutive year, the opportunity to discuss its different programs centered in Lysine specific demethylase 1 (LSD1, KDM1A), an epigenetic modulator able to regulate gene expression by demethylating histones, with industry leaders and investors.

Dr. Carlos Buesa will also present in a parallel meeting, *Biotech Showcase 2014*, that takes place at the Parc55 Wyndham-Union Square Hotel, the most recent advances in one of Oryzon's leading programs under the title "**LSD1 Inhibition stops cognitive impairment in Neurodegenerative Diseases**". This presentation will take place on Jan 15th 2014 at 9:45:00 on the Track B - Mission I (4th Floor) at the Parc55 Wyndham-Union Square Hotel.

LSD1 forms part of protein complexes involved in transcriptional regulation, and mis-regulation of these transcriptional complexes may result in disease. Molecules discovered and developed by Oryzon have shown efficacy in the treatment of acute myeloid leukemia (AML). Oryzon's forerunner molecule, ORY-1001, is low nM LSD1 inhibitor, highly selective and with excellent pharmacological characteristics. ORY-1001 reduces leukemic stem cell potential, potently inhibits colony formation, overcomes the differentiation block in AML cell lines, and induces apoptosis / inhibits proliferation at sub-nanomolar concentrations in

selected AML cell lines. ORY-1001 has successfully passed the regulatory toxicology IND enabling studies and is starting Clinical Phase I/IIa trials.

But the potential use of LSD1 inhibitors is not limited to oncological diseases. LSD1 is well known to partner with Co-REST and REST/NRSF, a gene involved in the repression of neuronal genes in non-neuronal cells. Aberrant levels or activity of REST/Co-REST complexes have been implicated in different neurodegenerative diseases like Huntington's disease, Rett syndrome and increased REST expression has been found in the brain of Alzheimer's disease patients. Data in animal models of these neurodegenerative disorders obtained with Oryzon's CNS candidate ORY-2001 will be presented.

Epigenetics is a hot spot field in the pharmaceutical industry. It is predicted that world revenues for epigenetic therapies and technologies will reach \$2.73bn in 2015 and that the overall market will grow with a CAGR of 16% between 2010 and 2015. Therapies will remain the largest source of revenue in the epigenetics market. The deal activity on the field is intense.

Oryzon Genomics is the global leader in Histone Lysine Demethylases with a special emphasis on Lysine Specific Demethylases (LSD1 and LSD2). LSD1 is a flavin dependent amine oxidase capable of selective demethylation of Lys-4 of histone H3. LSD1 has been proposed as a target for oncology, viral diseases and neurodegeneration. Oryzon has a wide drug-discovery program on LSD1 with around 900 compounds made and tested and two candidates in development. According to Carlos Buesa, C.E.O. of the company. *"Oryzon's compounds are the most potent LSD1 inhibitors described, and we have identified now a subset of diseases in which this mechanism looks particularly efficient. The company has a dominant patent position in LSD1 with 18 patent families and we are really happy to communicate to the Epigenetic community our progresses and the potential of LSD1 as a therapeutic target in different devastating diseases. For any company willing to play a role in these indications we are the partner of choice"*

### **About Oryzon**

Founded in 2000, Oryzon ([www.oryzon.com](http://www.oryzon.com)) is currently the European champion in Epigenetics. The company has one of the most complete technological platforms for biomarker identification in Europe. With a core in genomics, the company has a powerful platform for biomarker and target validation which includes technologies such as RNAi, and a structural genomic platform with a fragment screening approach (NMR and X ray crystallography). The company identifies biomarkers for a variety of neoplastic and neurodegenerative diseases and develops new drugs against these targets till Phase II.

### **For further information, please contact:**

**Emili Torrell**

**Business Development Officer**

**Tel. +34 93 515 13 13**

**[etorrell@oryzon.com](mailto:etorrell@oryzon.com)**

*Key words: Epigenetics, LSD1, AML, leukemia, Alzheimer, ORYZON, Phase I/IIA, 32nd ANNUAL J.P. MORGAN Healthcare Conference, Biotech Showcase 2014.*